Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

Psychiatry Research

Volumn 69, Issue 2-3, 1997, Pages 105-111

  Lane, Hsien Yuan ^a   Hu, Oliver Yoa Pu ^a   Jann, Michael W ^b   Deng, Hwei Chuang ^c   Lin, Hsin Nan ^d   Chang, Wen Ho ^c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b MERCER UNIVERSITY   (United States)

^c TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dextromethorphan; Extrapyramidal side effects; Reduced haloperidol; Schizophrenia

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASAL GANGLIA DISEASES; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALOPERIDOL; HUMANS; MALE; PHENOTYPE; SCHIZOPHRENIA;

EID: 0030903753     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(96)02999-X     Document Type: Article

References (37)

1. Altamura, A.C. (1993) A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: with particular reference to drug resistance. Schizophr Res 8, 187-198.
2. Binder, R.L. and Levy, R. (1981) Extrapyramidal reactions in Asians. Am J Psychiatry 138, 1243-1244.
3. Bowen, W.D., Moses, E.L., Tolentino, P.J. and Walker, J.M. (1990) Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D2 receptor. Eur J Pharmacol 177, 111-118.
4. Brent, P.J. (1994) Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea pigs correlates with inhibition of sigma binding sites. Neuropsychopharmacology 10, 134S.
5. Chang, W.H. (1992) Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology 106, 289-296.
6. Chang, W.H., Hwu, H.G., Lane, H.Y., Lin, S.K., Chen, T.Y., Chen, H., Wei, H.L. and Lin, H.N. (1991) Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Psychiatry Res 38, 215-225.
7. Chang, W.H., Lin, S.H., Jann, M.W., Lam, Y.W.F., Chen, T.Y., Hu, W.H. and Yeh, E.K. (1989) Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol Psychiatry 26, 239-249.
8. Conley, R., An Nguyen, J. and Tamminga, C. (1991) Haloperidol kinetics and clinical response. Schizophr Res 4, 287.
9. Evans, D.A., Mahgoub, A., Sloan, T.P., Idle, J.R. and Smith, R.L. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17, 102-105.
10. Frèche, J.P., Dragacci, S., Petit, A.M., Siest, J.P., Galteau, M.M. and Siest, G. (1990) Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population. Eur J Clin Pharmacol 39, 481-485.
11. Froemming, J.H., Lam, Y.W.F., Jann, M.W. and Davis, C.M. (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17, 396-423.
12. Henthorn, T.K., Benitez, J., Avram, M.J., Martinez, G., Llerena, A., Cobaleda, J., Krejcie, T.C. and Gibbons, R.D. (1989) Assessment of the debrisoquin and dextromethorphan phenotyping tests by Gaussian mixture distributions analysis. Clin Pharmacol Ther 45, 328-333.
13. Hildebrand, M., Seifert, W. and Reichenberger, A. (1989) Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36, 315-318.
14. Inaba, T. and Kovacs, J. (1989) Haloperidol reductase in human guinea pig livers. Drug Metab Dispos 17, 330-333.
15. Irshaid, Y.M., Al-Hadidi, H.F. and Rawashdeh, N.M. (1993) Dextromethorphan O-demethylation polymorphism in Jordanians. Eur J Pharmacol 45, 271-273.
16. Jann, M.W., Chang, W.H., Davis, C.M., Chen, T.Y., Deng, H.C., Lung, F.W., Ereshefsky, L., Saklad, S.R. and Richards, A.L. (1989) Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res 30, 45-52.
17. Jann, M.W. and Grimsley, S.R. (1993) Pharmacogenetics of agents acting on the central nervous system. J Pharm Pract 6, 2-16.
18. Lam, Y.W.F. and Rodriquez, S.Y. (1993) HPLC determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 15, 300-304.
19. Lane, H.Y., Deng, H.C., Huang, S.M., Hu, W.H., Chang, W.H. and Hu, O.Y.P. (1996) Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin Pharmacol Ther 60, 696-698.
20. Lane, H.Y., Lin, H.N., Hwu, H.G., Jann, M.W., Hu, W.H. and Chang, W.H. (1995) Haloperidol plasma concentrations in Taiwanese psychiatric patients. J Formos Med Assoc 94, 671-678.
21. Larrey, D., Amouyal, G., Tinel, M., Letteron, P.,Berson, A., Labbe, G. and Pessayre, D. (1987) Polymorphism of dextromethorphan oxidation in French population. Br J Clin Pharmacol 24, 676-679.
22. Lin, K.M. and Finder, E. (1983) Neuroleptic dosage for Asians. Am J Psychiatry 140, 490-491.
23. Lingjaerde, O., Ahlfors, U.G., Bech, P., Dencker, S.J. and Eigen, K. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76 (suppl 334), 1-100.
24. LLerena, A., Alm, C., Dahl, M.L., Ekqvist, B. and Bertilsson, L. (1992a) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14, 92-97.
25. LLerena, A., Dahl, M.L., Ekqvist, B. and Bertilsson, L. (1992b) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14, 261-264.
26. Lou, Y.C., Ying, L., Bertilsson, L. and Sjöqvist, F. (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2, 852-853.
27. Marinac, J.S., Foxworth, J.W. and Willsie, S.K. (1995) Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects. Ther Drug Monit 17, 120-124.
28. Overall, J.E. and Gorham, D.R. (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10, 799-812.
29. Schmid, B., Bircher, J., Preisig, R. and Kupfer, A. (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38, 618-624.
30. Steiner, E., Bertilsson, L., Sawe, J., Bertling, I. and Sjöqvist, F. (1988) Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44, 431-435.
31. Straka, R.J., Hansen, S.R. and Walker, P.F. (1995)Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin Pharmacol Ther 58, 29-34.
32. Syvälahti, E.K.G., Lindberg, R., Kallio, J. and De Vocht, M. (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation. Br J Clin Pharmacol 2, 89-92.
33. Tsang, M.W., Shader, R.I. and Greenblatt, D.J. (1994) Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 14, 159-162.
34. Tyndale, R.F., Kalow, W. and Inaba, T. (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6. Br J Clin Pharmacol 31, 655-660.
35. Volavka, J. and Cooper, T.B. (1987) Review of haloperidol blood level and clinical response: looking through the windows. J Clin Psychopharmacol 7, 25-30.
36. Volavka, J., Cooper, T.B., Czobor, P., Bitter, I., Meiser, M., Lsaka, E., Gastanaga, P., Krakowski, M., Chou, J., Crowner, M. and Ouyon, R. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49, 354-361.
37. Wang, S.L., Huang, J.D., Lai, M.D., Liu, B.H. and Lai, M.L. (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53, 410-418.